Quest Laboratories Limited — PPTs, 28-12-2024: Investor Presentation

**Financial Highlights:** Quest Laboratories reported revenue of ₹42.63 crore for H1 FY25, up from ₹41.02 crore in H1 FY24, with EBITDA growing 29.13% to ₹12.19 crore and PAT increasing by 26.74% to ₹8.01 crore. EBITDA margin improved to 28.07%, up 508.66 basis points, reflecting enhanced operational efficiency.

**Strategic Initiatives and Growth Drivers:** The company is set to expand manufacturing capacity through two new plants and is actively working on product registrations in Myanmar, Cambodia, and Kenya, among other countries. A substantial order book of ₹25 crore from Myanmar indicates strong market demand.

**Business Developments:** Quest is diversifying its product offerings with the introduction of capsules and a collagen segment, expected to commence production by late 2024 and April 2025, respectively. This strategic move is projected to contribute significantly to revenues.

**Market Position and Competitive Advantage:** With over 800 licensed formulations and a strong domestic market presence, the company is well-positioned to capitalize on the growing global demand for pharmaceutical products, especially generic drugs.

**Investor Implications:** The positive financial trajectory and diversification strategy suggest a favorable outlook for Quest Laboratories. Projected revenue growth of 30-35% CAGR in the next three years, along with expanding export contributions, make Quest an intriguing consideration for retail investors seeking opportunities in the pharmaceutical sector.